❤️‍🔥Wrapping up #ASNC2026 Las Vegas... Have a safe flight back home everyone ✈️ 🏠
🌟Next stop: Orlando, Fl🔥 #ASNC2027 , Sept 9-12 2027. Save the date📅 @MyASNC

Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy

Acoramidis initiation resulted in an acute dip in eGFR and reductions in both the chronic eGFR slope and urinary albumin-to-creatinine ratio versus placebo without adverse kidney-related events. idney function may be mediated through direct kidney-protective hemodynamic effects.
@MasriAhmadMD @CMichaelGibson @CircHF @hfcollaboratory @GianluSava @AndrewJSauer
ahajournals.org/doi/10.1161/CI…

Check out what's to come next month at ISA 2026! This session explores the latest research on AA amyloidosis, genetic studies, prognostic markers, and treatment strategies.

View the full meeting program to discover more:
isaamyloidosis.org/isa-2026-sympo…

🫀 Cardiac PET Quiz #01

86F referred for dyspnea.
Rb-82 PET, regadenoson stress.

• Perfusion: normal
• No TID, no EF drop
• Heavy multivessel CAC on the CT
• Global MFR 1.12 😬

Balanced 3VD? Not so fast.
The spleen switches off at stress.

What would you check next?

A) Go b
B) Hemodynamics during stress
C) Caffeine history
D) Treat as CMD

Answer in the replies 👇
Commit to one before you peek.

#CardiacPET #NuclearCardiology #CVImaging #MedEd

Beyond coronary stenosis: How can we better predict cardiovascular risk?

Excellent Grand Rounds today at @BrighamWomens with Dr. Bernard Gersh. @BernardGersh

Key insights on plaque burden, vulnerable plaques, the PREVENT trial, and advanced CCTA imaging.

The future lies in ysiology, and inflammation.

A few takeaways 🧵👇

Join us Sunday, 11/8, at 5:30 PM CST for our #CardiacAmyloidosis live in-person & virtual symposium featuring Ahmad Masri, MD, MS (@MasriAhmadMD), Margot K. Davis, MD, & Daniel P. Judge, MD, during the AHA #ScientificSessions26 bit.ly/26-ATTR-T #cardiology #MedEd

🫀 Can clinically important cardiac sarcoidosis occur without LGE on CMR?

Our new short report in European Heart Journal – Imaging Methods and Practice addresses this question.

The added value of FDG-PET when LGE is absent has been questioned.

🇨🇦 In a single-centre substudy of S cohort, we examined 46 treatment-naïve patients with clinically manifest cardiac sarcoidosis and core-lab-defined abnormal cardiac AND extracardiac FDG uptake.

🔎 What did we find?
4/46 patients (8.7%) had no LGE
All four presented with advanced AV conduction disease

"No LGE does not necessarily mean no clinically important cardiac sarcoidosis."

⚠️ This small, selected cohort does not establish poor long-term prognosis or justify PET for everyone without LGE. It supports considering FDG-PET when clinical suspicion remains high despite absent LGE.

Grateful to all our coauthors for this work, and looking forward to the CHASM-CS RCT results on treatment strategies!

#CardiacSarcoidosis #WhyCMR #ThinkPET #CVNuc
#HeartInstitute @MyASNC

Transforming systemic amyloid (ATTR and AL) into treatable diseases (not curable yet). Less than 9 years ago there were no proven treatments for ATTR, and limited options for AL, now we are debating combo vs mono, different lines of therapy, earlier identification, when should we treat vs observe, running prevention trials and highly specific PET tracer trials.

Still lots of work to do. Depleters, imaging, biomarkers, rare amyloids, light chain stabilizers, new silencers, gene editing ......

CARDIO-TTRansform narrowly missed its main goal overall, but the results tell a more nuanced story. What did we learn about eplontersen, stabilizer use, and combination therapy in ATTR-CM?

Read ARC’s perspective:
arci.org/cardio-ttransf…

Our first session is underway with @JLGrodin discussing advances in ATTR amyloidosis and the challenges that remain. The shift from biopsy-based to nonbiopsy diagnosis is creating opportunities to identify patients earlier.
#AmyloidosisForum

Our first moderated discussion tackles ATTR trial design: Do composite endpoints capture residual burden and when treatment benefit emerges? Are hard outcomes improving? How does enrichment affect generalizability? #AmyloidosisForum

Composite endpoints should reflect patients’ experiences. In systemic ATTR, quality of life is shaped by more than heart failure or heart function. Measures that worked in earlier trials may need to evolve with today’s treatment landscape. #AmyloidosisForum

Our second #AmyloidosisForum session is underway! @DorbalaSharmila opens the discussion on imaging in amyloidosis with a big question: Is it time to redefine amyloidosis?

Dr. Steven Rowe draws on nuclear imaging in prostate cancer to explore its potential in amyloidosis, from visual interpretation to quantification and imaging endpoints. A key challenge: what scans show may not align with a patient’s clinical findings. #AmyloidosisForum

After a decade of imaging patients in amyloidosis trials, what would it take for the next five years to change care? The panel called for turning the imaging data we already have into measures that can guide treatment and show what matters to patients. #AmyloidosisForum

With amyloid-depleting therapies on the horizon, imaging may play a larger role in assessing treatment. The panel discussed a key research need: linking amyloid burden with disease trajectory and biomarkers to identify which patients are progressing. #AmyloidosisForum

Could treating ATTRwt before significant symptoms prevent organ damage? How do we identify who would benefit? The panel emphasized the need for more data and prospective trials to answer these questions for patients with minimal or no symptoms. #AmyloidosisForum

The #AmyloidosisArmy brings the patient perspective to the Forum: Can imaging help detect progression before organ damage occurs? And how can that information guide decisions that matter most to patients and their families? #AmyloidosisForum

Living with wild-type ATTR amyloidosis but not currently eligible for treatment because there’s no cardiac involvement.
ARC wants to hear from you!

Take and share the 2026 Community Survey: arci.org/survey2026/

#ATTRwt #Amyloidosis

When is a trial score change meaningful to patients? Are within-patient changes meaningful, the anchors valid, and composite domains moving together? These questions are vital when a patient-reported measure is the primary endpoint. #AmyloidosisForum

The ARC team at #AmyloidosisForum! Today’s discussions connected earlier diagnosis, imaging, trial design and meaningful treatment benefit. The shared priority: turn data into evidence that reflects patients’ lives—and use it to move care forward.